CytRx Corporation (CYTR)

0.31
OTC Markets
Prev Close 0.33
Day Low/High 0.31 / 0.33
52 Wk Low/High 0.26 / 1.10
Exchange OTC Markets
Shares Outstanding 33.64B
Market Cap 11.10M
Div & Yield N.A. (N.A)
5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Top Insider Trades: CYTR TROX KTOS MDGN

Top Insider Trades: CYTR TROX KTOS MDGN

The top 10 open-market insider purchases and sales filed at the SEC Tuesday.

CytRx Corporation To Present At The Oppenheimer 24th Annual Healthcare Conference On Wednesday, December 11th, 2013

CytRx Corporation To Present At The Oppenheimer 24th Annual Healthcare Conference On Wednesday, December 11th, 2013

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A.

CytRx To Present At The Sixth Annual LD MICRO “Main Event” Conference In Los Angeles On December 3, 2013

CytRx To Present At The Sixth Annual LD MICRO “Main Event” Conference In Los Angeles On December 3, 2013

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A.

CytRx Initiates Phase 2 Clinical Trial With Aldoxorubicin In Patients With Unresectable Glioblastoma Multiforme (Brain Cancer)

CytRx Initiates Phase 2 Clinical Trial With Aldoxorubicin In Patients With Unresectable Glioblastoma Multiforme (Brain Cancer)

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced initiation of a Phase 2 clinical trial with the Company’s aldoxorubicin for the ...

CytRx Reports Further Positive Interim Data From Global Phase 2b Clinical Trial With Aldoxorubicin Versus Doxorubicin As First-Line Therapy In Advanced Soft Tissue Sarcomas

CytRx Reports Further Positive Interim Data From Global Phase 2b Clinical Trial With Aldoxorubicin Versus Doxorubicin As First-Line Therapy In Advanced Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announces further positive clinical data from a multi-site global Phase 2b study comparing the ...

CytRx Reports 2013 Third Quarter Financial Results

CytRx Reports 2013 Third Quarter Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and nine-month periods ended September 30, 2013, ...

Global Phase 2b Clinical Data For CytRx’s Aldoxorubicin To Be Featured At The Connective Tissue Oncology Society Annual Meeting

Global Phase 2b Clinical Data For CytRx’s Aldoxorubicin To Be Featured At The Connective Tissue Oncology Society Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that additional preliminary data from its Phase 2b clinical trial demonstrating...

CytRx Announces Closing Of Public Offering Of Common Stock

CytRx Announces Closing Of Public Offering Of Common Stock

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the closing of its previously announced underwritten public offering.

CytRx Announces Exercise Of Underwriters’ Over-Allotment Option

CytRx Announces Exercise Of Underwriters’ Over-Allotment Option

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the sale of an additional 1.

CytRx Announces Pricing Of Public Offering Of 10.0 Million Shares Of Common Stock

CytRx Announces Pricing Of Public Offering Of 10.0 Million Shares Of Common Stock

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the pricing of its previously announced underwritten public offering.

CytRx Announces Proposed Public Offering Of Common Stock

CytRx Announces Proposed Public Offering Of Common Stock

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced its intention, subject to market and other conditions, to commence a public offering of...

CytRx’s New Aldoxorubicin Data Demonstrates Significant Advantages Over Doxorubicin

CytRx’s New Aldoxorubicin Data Demonstrates Significant Advantages Over Doxorubicin

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced compelling preliminary data from its global Phase 2b soft tissue sarcoma trial ...

CytRx To Present At The Aegis Capital Corp. 2013 Healthcare Conference

CytRx To Present At The Aegis Capital Corp. 2013 Healthcare Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

CytRx To Present At The Rodman & Renshaw Global Investment Conference

CytRx To Present At The Rodman & Renshaw Global Investment Conference

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, announces that President and CEO Steven A.

CytRx Reports 2013 Second Quarter Financial Results

CytRx Reports 2013 Second Quarter Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and six months ended June 30, 2013, and provided a ...

CytRx’s Aldoxorubicin Shrinks Tumors And Prolongs Survival In Model Of Human Brain Cancer

CytRx’s Aldoxorubicin Shrinks Tumors And Prolongs Survival In Model Of Human Brain Cancer

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin, its more potent version of the widely used chemotherapeutic...

CytRx Reaches Enrollment Target In International Phase 2b Clinical Trial With Aldoxorubicin As First-Line Treatment For Soft Tissue Sarcoma

CytRx Reaches Enrollment Target In International Phase 2b Clinical Trial With Aldoxorubicin As First-Line Treatment For Soft Tissue Sarcoma

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that it has reached the targeted enrollment of 105 evaluable patients in its ...

CytRx’s Executive Vice President And Chief Medical Officer Dr. Daniel Levitt To Present Oncology Grand Rounds At LSU Medical School

CytRx’s Executive Vice President And Chief Medical Officer Dr. Daniel Levitt To Present Oncology Grand Rounds At LSU Medical School

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that Executive Vice President and Chief Medical Officer Daniel Levitt, M.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

CytRx To Present At The 25th Annual ROTH Conference

CytRx To Present At The 25th Annual ROTH Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and CEO Steven A.

CytRx Reports 2012 Financial Results

CytRx Reports 2012 Financial Results

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the 12 months ended December 31, 2012, and provided 2013 ...

CytRx To Present At The Cowen & Company 33rd Annual Health Care Conference

CytRx To Present At The Cowen & Company 33rd Annual Health Care Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that Vice President of Business Development David J.

8 Stocks Under $10 Moving Higher

8 Stocks Under $10 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

CytRx Reaches Patient Enrollment Target In Global Phase 2b Clinical Trial With Tamibarotene As First-Line Treatment For Non-Small-Cell Lung Cancer

CytRx Reaches Patient Enrollment Target In Global Phase 2b Clinical Trial With Tamibarotene As First-Line Treatment For Non-Small-Cell Lung Cancer

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that enrollment of 140 evaluable patients has been completed in the Company’s global ...

CytRx To Present At The 2013 Leerink Swann Global Healthcare Conference

CytRx To Present At The 2013 Leerink Swann Global Healthcare Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and CEO Steven A.

CytRx To Present At The BIO CEO & Investor Conference

CytRx To Present At The BIO CEO & Investor Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and Chief Executive Officer Steven A.

CytRx Receives Recommendation From Data Safety Monitoring Committee To Complete Global Phase 2b Clinical Trial With Tamibarotene As First-Line Treatment For Non-Small-Cell Lung Cancer

CytRx Receives Recommendation From Data Safety Monitoring Committee To Complete Global Phase 2b Clinical Trial With Tamibarotene As First-Line Treatment For Non-Small-Cell Lung Cancer

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that the Data Safety Monitoring Committee overseeing the Company’s global Phase 2b ...

CytRx Announces Positive Results From Animal Trial With Combination Aldoxorubicin And Doxorubicin Therapy

CytRx Announces Positive Results From Animal Trial With Combination Aldoxorubicin And Doxorubicin Therapy

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that an in vivo trial investigating aldoxorubicin, its tumor-targeting conjugate of...